marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-13-2024
Seres Therapeutics Balance Sheet 2011-2024 | MCRB
Annual Balance Sheet Seres Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-11.3 M | -51.5 M | -163 M | -86.3 M | -10.8 M | -78.6 M | -27.1 M | -54.5 M | -73.9 M | -112 M | -816 K | - | - |
Long Term Debt |
110 M | 108 M | 18 M | 24.6 M | 24.6 M | - | - | - | - | 1.3 M | 438 K | - | - |
Long Term Debt Current |
6.68 M | 3.6 M | 6.61 M | 5.12 M | 4.46 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 135 M | 126 M | 97.2 M | 110 M | 586 K | 139 M | 12.2 M | - | - |
Total Current Liabilities |
98.7 M | 85.6 M | 82.3 M | 46.4 M | 46 M | 42 M | 31.6 M | 30.5 M | 10.9 M | - | - | - | - |
Total Liabilities |
403 M | 338 M | 223 M | 168 M | 181 M | 169 M | 129 M | 140 M | 11.5 M | 144 M | 13.2 M | - | - |
Deferred Revenue |
- | - | - | - | 25.8 M | 20.4 M | 12.1 M | 12.1 M | - | - | - | - | - |
Retained Earnings |
-978 M | -865 M | -614 M | -549 M | -460 M | -389 M | -264 M | -174 M | -82.6 M | -27.8 M | -11.1 M | - | - |
Total Assets |
359 M | 349 M | 355 M | 343 M | 132 M | 120 M | 190 M | 273 M | 217 M | 117 M | 2.12 M | - | - |
Cash and Cash Equivalents |
128 M | 163 M | 188 M | 116 M | 65.1 M | 85.8 M | 36.1 M | 54.5 M | 73.9 M | 114 M | 1.65 M | - | - |
Book Value |
-44.9 M | 10.8 M | 132 M | 175 M | -48.3 M | -48 M | 60.7 M | 133 M | 205 M | -26.7 M | -11.1 M | - | - |
Total Shareholders Equity |
-44.9 M | 10.8 M | 132 M | 175 M | -48.3 M | -48 M | 60.7 M | 133 M | 205 M | -26.7 M | -11.1 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Seres Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
110 M | 110 M | 106 M | 110 M | 110 M | 50 M | 108 M | 50 M | - | 50 M | 18 M | 25 M | 25 M | 25 M | 25 M | 25 M | 25 M | 25 M | 25 M | 15.7 M | 15.7 M | 15.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
409 M | 401 M | 403 M | 383 M | 384 M | 318 M | 338 M | 244 M | - | 239 M | 223 M | 221 M | 169 M | 162 M | 168 M | 168 M | 168 M | 168 M | 181 M | 181 M | 181 M | 181 M | 169 M | 169 M | 169 M | 169 M | 129 M | 129 M | 129 M | 129 M | 140 M | 140 M | 140 M | 140 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 7.99 M | 7.99 M | 7.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.78 M | 5.65 M | 4.86 M | 4.83 M | 4.83 M | 4.83 M | 4.83 M | 20.4 M | 17.9 M | 18 M | - | 12.1 M | 12.1 M | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.05 B | -1.02 B | -978 M | -937 M | -889 M | -936 M | -865 M | -796 M | - | -671 M | -614 M | -564 M | -633 M | -584 M | -549 M | -549 M | -549 M | -549 M | -460 M | -460 M | -460 M | -460 M | -389 M | -389 M | -389 M | -389 M | -264 M | -264 M | -264 M | -264 M | -174 M | -174 M | -174 M | -174 M | -82.6 M | -82.6 M | -82.6 M | -82.6 M | -27.8 M | -27.8 M | -27.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
322 M | 341 M | 359 M | 368 M | 406 M | 270 M | 349 M | 312 M | - | 320 M | 355 M | 396 M | 270 M | 306 M | 343 M | 343 M | 343 M | 343 M | 132 M | 132 M | 132 M | 132 M | 120 M | 120 M | 120 M | 120 M | 190 M | 190 M | 190 M | 190 M | 273 M | 273 M | 273 M | 273 M | 217 M | 217 M | 217 M | 217 M | 117 M | 117 M | 117 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
71.2 M | 111 M | 128 M | 170 M | 238 M | 103 M | 163 M | 214 M | 135 M | 161 M | 180 M | 227 M | 74 M | 66.6 M | 116 M | 116 M | 116 M | 116 M | 65.1 M | 65.1 M | 65.1 M | 65.1 M | 85.8 M | 85.8 M | 85.8 M | 85.8 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 73.9 M | 73.9 M | 73.9 M | 73.9 M | 114 M | 114 M | 114 M | - | 1.65 M | - | - | - | 6.22 M | - | - | - | - | - | - | - |
Book Value |
-87.1 M | -59.7 M | -44.9 M | -15.1 M | 22.6 M | -47.9 M | 10.8 M | 67.6 M | - | 81 M | 132 M | 176 M | 101 M | 144 M | 175 M | 175 M | 175 M | 175 M | -48.3 M | -48.3 M | -48.3 M | -48.3 M | -48 M | -48 M | -48 M | -48 M | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 133 M | 133 M | 133 M | 133 M | 205 M | 205 M | 205 M | 205 M | 109 M | 109 M | 109 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-87.1 M | -59.7 M | -44.9 M | -15.1 M | 22.6 M | -47.9 M | 10.8 M | 67.6 M | 23.1 M | 81 M | 132 M | 176 M | 101 M | 144 M | 175 M | 175 M | 175 M | 175 M | -48.3 M | -48.3 M | -48.3 M | -48.3 M | -48 M | -48 M | -48 M | -48 M | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 133 M | 133 M | 133 M | 133 M | 205 M | 205 M | 205 M | 205 M | -26.7 M | -26.7 M | -26.7 M | - | -11.1 M | - | - | - | -4.35 M | - | - | - | - | - | - | - |
All numbers in USD currency